Peritoneal cancer index

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
4 Unique sponsors
8 Unique IMPs
4 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 4
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (rat) 1 substance
Monoclonal antibody (immune) 1 substance
Phase III: 1 Phase II: 2 Phase I (First in Human): 2

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Mural Oncology Inc. Commercial
    NEMVALEUKIN ALFA; PEMBROLIZUMAB
    2024-513230-38-00 10 countries 2022 n=244
    Ended

Phase II

2 trials
  • Merck Sharp & Dohme LLC Commercial
    MK-4830; PEMBROLIZUMAB
    2023-505005-16-00 4 countries 2022 n=32
    Ended
  • Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic
    PEMBROLIZUMAB
    2023-508155-40-00 1 country 2022 n=33
    Ended

Phase I (First in Human)

2 trials
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB, FIANLIMAB; REGN5668; SARILUMAB; UBAMATAMAB
    2022-501904-83-00 3 countries 2023 n=208
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB; SARILUMAB; UBAMATAMAB
    2024-510783-23-00 5 countries 2020 n=237
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Regeneron Pharmaceuticals Inc. Commercial 2 Phase I (First in Human) 2
Merck Sharp & Dohme LLC Commercial 1 Phase II 0
Mural Oncology Inc. Commercial 1 Phase III 0
Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic 1 Phase II 0
New trials by year
2020
1
2022
3
2023
1
← All indication landscapes